ArticlePloS one2025
Global and Chinese epidemiologic study of polycystic ovary syndrome in women of childbearing age, 1990-2021, and projections to 2035: Based on the Global Burden of Disease 2021 study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of Fisetin in the Mammalian Reproductive System.Veterinary sciences · 2026Review
- Facing the diagnosis of hyperandrogenic polycystic ovary syndrome by a novel combination of circulating biomarkers.Scientific reports · 2026Article
- Trends in PCOS Incidence, Prevalence, and DALYs Across Five BRICS Nations, 1990-2050: A Decomposition, Age-Period-Cohort, and Bayesian Forecasting Analysis Based on GBD 2021.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to synthesize and analyze the burden of disease of polycystic ovary syndrome (PCOS) in women of reproductive age globally and in China from 1990 to 2021.
methodsThe study utilized data from the Global Burden of Disease 2021 database, which contains detailed epidemiologic information from 204 countries and territories. Incidence, prevalence and disability-adjusted life years (DALYs) of polycystic ovary syndrome (PCOS) were assessed. Bayesian age-period cohort modeling was applied to project trends in the burden of disease up to 2035.
resultsGlobal trend: the incidence of polycystic ovary syndrome (PCOS) increased slightly from 58.84/100,000 in 1990 to 60.30/100,000 in 2021. there was a significant increase in prevalence of 29.66% and an increase in disability-adjusted life-years (DALYs) of 28.37%. Trends in China: Despite a slight decrease in prevalence (-1.96%), the prevalence of polycystic ovary syndrome (PCOS) and the number of DALYs in China increased substantially by 86.95% and 86.56%, respectively. Sociodemographic impact: Countries with higher sociodemographic indices tend to face a higher burden of PCOS. Future projections: BAPC model projections suggest that the prevalence of PCOS will continue to increase globally and in China through 2035.
conclusionThese findings highlight the growing public health challenge posed by polycystic ovary syndrome and emphasize the need to strengthen early identification, health management, and lifestyle interventions, especially in areas with high SDI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.